title: Could Pin1 help us conquer essential hypertension at an earlier stage? A promising early-diagnostic biomarker and its therapeutic implications for the disease.
abstract: Essential hypertension is a major risk factor for cardiovascular morbidity and mortality, and the early-diagnosis is very important for the prevention of essential hypertension. Previously, we found that Pin1, the only known enzyme isomerizing pSer/pThr-Pro motifs in proteins, may gradually become inactive under conditions of stress such as intracellular acidification and fever. Interestingly, essential hypertension and the dysfunction of Pin1 often synchronously occur with the increasing age. Recent evidence indicates that Pin1 primarily increases the activity of endothelial nitric oxide synthase (eNOS) and the production of nitric oxide (NO) in multiple ways, significantly promoting the relaxation response of blood vessels and preventing the elevation of blood pressure. Further, the inhibition of Pin1 results in significantly increased blood pressure in rats. So, we hypothesized and evaluated the potential of Pin1 to be a new early-diagnostic biomarker as well as a therapeutic drug for essential hypertension. The unique activity of Pin1 and some epidemiological and experimental data evidence that the decreased activity of Pin1 may be closely associated with the development of essential hypertension. The factors that may impact the activity of Pin1 and correlate with the risk of essential hypertension were also discussed. These findings indicate that Pin1 plays a key and permanent role in efficiently preventing the development of essential hypertension, and that Pin1 may be a promising early-diagnostic biomarker as well as an effective therapeutic drug for the early-diagnosis, prevention, and treatment of essential hypertension, potentially decreasing the risk of cardiovascular morbidity and mortality.
authors.affiliation: Department of Medical Technology, Medical College, Hebei University of Engineering, Handan 056038, PR China. Electronic address: wangjingzhang1981@gmail.com.
authors.forename: Jing-Zhang
authors.initials: JZ
authors.lastname: Wang
authors.forename: Shu-Rui
authors.initials: SR
authors.lastname: Li
authors.forename: Ya-Li
authors.initials: YL
authors.lastname: Li
authors.forename: Yong-Ze
authors.initials: YZ
authors.lastname: Zhang
authors.forename: Ting
authors.initials: T
authors.lastname: Zhang
authors.forename: Chao-Xian
authors.initials: CX
authors.lastname: Zhao
authors.forename: Chun-Xia
authors.initials: CX
authors.lastname: Yao
authors.forename: Lin-Fang
authors.initials: LF
authors.lastname: Du
mesh_terms: D000367:Age Factors; D015415:Biomarkers / Q000378:metabolism*; D000075222:Essential Hypertension; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy*; D008954:Models, Biological; D000072340:NIMA-Interacting Peptidylprolyl Isomerase; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D019696:Peptidylprolyl Isomerase / Q000378:metabolism / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D000072340:NIMA-Interacting Peptidylprolyl Isomerase; D014665:Vasodilator Agents; D052250:Nitric Oxide Synthase Type III; C000606846:PIN1 protein, human; D019696:Peptidylprolyl Isomerase
keywords: AD; Alzheimer’s disease; Aβ; NO; PBMC; PPIase; TGF-β; VEGF; amyloid-beta; eNOS and iNOS; endothelial and inducible nitric oxide synthase, respectively; nitric oxide; peptidyl-prolyl cis–trans isomerase; peripheral blood mononuclear cells; transforming growth factor-beta; vascular endothelial growth factor